Exicure to Present Phase 2 Clinical Data for Multiple Myeloma Treatment at US Tandem Meetings

Nasdaq-listed company Exicure announced on January 22, citing foreign media sources, that it will present a poster featuring Phase 2 clinical trial data for Burixafor (GPC-100), a compound developed by the company, at the 2026 Tandem Meetings, a bio-academic conference to be held in Salt Lake City, United States, from February 4 to 7.

Burixafor (GPC-100) is a drug designed to block the chemokine receptor CXCR4, thereby mobilizing hematopoietic progenitor cells (HPCs) from the bone marrow into the peripheral blood. According to the company, these mobilized stem cells can be collected during the preparation process for autologous hematopoietic cell transplantation (AHCT), potentially making cell collection easier compared to existing treatment methods.

The company stated that Burixafor was administered in combination with Propranolol and G-CSF, and this combination therapy met the primary endpoint (successful stem cell mobilization) in more than 89.7% of patients.

The poster is titled "Phase 2 Study Evaluating the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF." The presentation will be delivered by Dr. Yosra Alzawi of the University of Texas MD Anderson Cancer Center, which has been ranked number one in the field of oncology by US News and participated in this clinical trial.

The company added, "GPC-100 is being evaluated as a stem cell mobilizer in various fields, including not only multiple myeloma but also sickle cell disease and cell and gene therapy. In particular, a clinical trial is also being planned to improve chemosensitivity by mobilizing malignant cells residing in the bone marrow niche into the peripheral blood in acute myeloid leukemia (AML). Given the similarity to the multiple myeloma trial, we believe the likelihood of success is also very high."